Molecular Targeting in Oncology
Humana Press Inc. (Verlag)
978-1-58829-577-4 (ISBN)
The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more.
General Strategies for Molecular Targeting in Oncology.- The Cell Cycle.- mTOR.- Ras/Raf/MEK Inhibitors.- 17-AAG.- The Cancer Epigenome.- Molecular Targeting for Specific Disease Sites.- Molecular Targeting in Upper Gastrointestinal Malignancies.- Molecular Targeting of Colorectal Cancer.- Molecular Targeting in Hepatocellular Carcinoma.- Molecularly Targeted Therapy in Pancreatic Cancer.- Untargeted Use of Targeted Therapy.- Renal Cell Carcinoma.- Targeted Therapies for Prostate Cancer.- Molecular Targets in Ovarian Cancer and Endometrial Cancer.- Targeted Therapy For Breast Cancer.- Melanoma.- Classes of Drugs for Molecular Targeting in Oncology.- Antibody Therapy of Cancer.- Nucleic Acid Therapies for Cancer Treatment.- Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy.- Vaccines as Targeted Cancer Therapy.- Cytokine-Based Therapy for Cancer.- Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment.- Specific Drugs for Molecular Targeting in Oncology.- Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations.- Development of a Targeted Treatment for Cancer.- VEGF Inhibition for Cancer Therapy.- Somatostatin Analogue Therapy.- Challenges in Molecular Targeting in Oncology.- Patient Selection for Rational Development of Novel Anticancer Agents.- Clinical Trial Design with Targeted Agents.- How to Define Treatment Success or Failure if Tumors Do Not Shrink.- Molecular Imaging in Oncology.- Combinations of Molecular-Targeted Therapies.- Preclinical Development of Molecularly Targeted Agents in Oncology.
Reihe/Serie | Cancer Drug Discovery and Development |
---|---|
Zusatzinfo | XVI, 728 p. |
Verlagsort | Totowa, NJ |
Sprache | englisch |
Maße | 178 x 254 mm |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Medizin / Pharmazie ► Pharmazie | |
Medizin / Pharmazie ► Studium | |
Naturwissenschaften ► Biologie ► Biochemie | |
ISBN-10 | 1-58829-577-X / 158829577X |
ISBN-13 | 978-1-58829-577-4 / 9781588295774 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich